Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma. The Company has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to change the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device. The Company is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression.

Type
Public
HQ
Laguna Hills, US
Founded
1998
Size (employees)
264 (est)+5%
Glaukos was founded in 1998 and is headquartered in Laguna Hills, US
Report incorrect company information

Key People/Management at Glaukos

Thomas Burns

Thomas Burns

President, Chief Executive Officer
Chris Calcaterra

Chris Calcaterra

COO
Joseph Gilliam

Joseph Gilliam

Chief Financial Officer, Senior Vice President, Corporate Development
Robert Davis

Robert Davis

Senior Vice President, General Counsel and Quality Affairs
Michele Allegretto

Michele Allegretto

Vice President, Human Resources
David Haffner

David Haffner

Senior Vice President, New Technologies
Show more

Glaukos Office Locations

Glaukos has offices in Neihu District, Pretoria, Singapore, Auckland and in 21 other locations
Laguna Hills, US (HQ)
26051 Merit Circle
Villa Crespo, AR
826 Tres Arroyos
Heatherton, AU
109 12 Corporate Dr
Alto de Pinheiros, BR
28 740 R. Gen. Furtado do Nascimento
Richmond Hill, CA
95 Mural St
San José, CR
Avenida 7, Calle 2
Show all (26)
Report incorrect company information

Glaukos Financials and Metrics

Glaukos Revenue

USD

Revenue (Q1, 2018)

40.1 m

Gross profit (Q1, 2018)

34.3 m

Gross profit margin (Q1, 2018), %

85.6%

EBIT (Q1, 2018)

(3.7 m)

Market capitalization (18-Jul-2018)

1.5 b

Closing share price (18-Jul-2018)

42.4

Cash (31-Mar-2018)

15.6 m
Glaukos's current market capitalization is $1.5 b.
USDQ1, 2018

Revenue

40.1 m

Cost of goods sold

5.8 m

Gross profit

34.3 m

Gross profit Margin, %

86%
USDQ1, 2018

Cash

15.6 m

Accounts Receivable

17.5 m

Inventories

12.8 m

Current Assets

147.4 m
USDQ1, 2018

Net Income

(2.7 m)

Depreciation and Amortization

1.7 m

Inventories

(1.5 m)

Accounts Payable

(8.1 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Glaukos Online and Social Media Presence

Embed Graph
Report incorrect company information

Glaukos Company Life and Culture

Report incorrect company information